We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting - very quick summary based on my understanding of each abstract. Purely IMO of course and I'm sure others will explain in more detail :)
A046 - relates to glycan mAB FG2811 and shows that it can activate TSCMs (stem memory T cells) with the potential to use them to create TCR/CAR T therapies
A185 - seems to be a summary of Modi1's MOA
A201 - GRP78 is a heat shock protein which is linked to autophagy and highly expressed in tumours. Citrullinated GRP78 is a potential target for Moditope - is this Modi3?
A212 - relates to Moditope. Blood from cancer patients and healthy volunteers was cultured with citrullinated/homocitrullinated peptides. Difference between the 2 groups suggests regulatory T cells (Tregs) may suppress immune response in some cancer patients - may need to be inhibited.
B203 - Modi2 and homocitrullination. Worth noting the role of MDSCs (myeloid derived suppressor cells) - highly immunosuppressive cells that are associated with a very poor prognosis and 'cold tumours'. The beauty of Modi2 is that these cells express MPO which generates Isocyanic acid which diffuses into the tumour and drives homocitrullination. So Moditope cleverly exploits MDSCs.
B223 - use of PEP-FOLD3 software which uses algos to screen and select epitopes for Moditope
A185 is interesting as is about the adjuvant of ISA's, Melief also in attendance at CICON19
' Linking the TLR2 agonists to the peptides allowed the vaccine dose to
be reduced 10-100 fold without loss of anti-tumor activity. These
studies suggest that low dose of citrullinated peptides linked to
TLR2 ligand should be rapidly translated to the clinic for the treatment of cancer. Furthermore, ovarian cancer patients show a CD4
proliferative response to one or more of the citrullinated peptides
which is similar to that in healthy donors. These results suggest
that Modi-1 could be an effective vaccine for ovarian cancer patients.'
promising for the upcoming trial
And not just titles ... can have a little read to try understand these latest abstracts
https://static1.squarespace.com/static/56dee71e555986fb3ae583e2/t/5d8939d1fd3ef815d5f998f0/1569274327669/Abstract+book+FINAL.pdf
Cheers TF
Oh nice, the titles are out, that is a whole lot of science there the understanding of moditope, in particular, grows and grows and all to be presented right under Sahin and Mellman's noses by the talents of team scancell science.... I too am not sure we will get an RNS for the event however with so many new abstracts to be presented by not just Lindy it is possible... as I think we all agree 6 abstracts is impressive .... As for what may come from of it well that is down to who is paying attention :) if Sahin sees Mellman make a b line for Lindy and gets all jealous things we want to happen could get a move on lol
I peeped at the 'Abstracts' - there's a stunning amount of research and many contributors to each paper. Some of Scancell's Abstracts have been selected for 'Poster Sessions'. Really good to see not only new Scancell names but also 'outside' contributors in the big 6 . . . .
Under Prof. Lindy, 6 abstracts are listed, I guess that confirms Scancell's total.
A046 / An ultraspecific monoclonal antibody recognises a novel marker on stem memory T cells and induce cell proliferation and differentiation in vitro and in vivo
A185 / Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells
A201 / Citrullinated glucose-regulated protein 78 is a can-didate target for cancer immunotherapy
A212 / Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized
B203 / Carbamylation of lysine residues mediated by myeloid derived suppressor cells in the tumor environ-ment make excellent targets for CD4 T cell mediated can-cer immunotherapy
B223 / Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms
I thought B223 most interesting so let's see if that helps our progress. An impressive 'Meet' indeed but WTP, I'm not expecting any commercial news coming or an RNS but you never know.
BioNTech have done well to get one session 'Chair' in place and 3 actual 'Presentations' . . . I'm surprised that Prof. Lindy is not presenting I suppose - she certainly has enough to talk about and a few drums to bang.
Come on Scancell ! GLA
Thank you for the reminder WTP and the link C7. Also, in the Program :-
Session 4: Immunotherapies, Non-Cell-Based
Session Chairperson: Ira Mellman
11:00 am - 11:25 am Mechanistic basis of cancer immunotherapy: checkpoints at 10. Ira Mellman, Genentech, San Francisco, California
11:25 am - 11:50 am Title not available. Ugur Sahin, BioNTech, Mainz, Germany
Session 8: Vaccination Strategies
Session Chairperson: Özlem Türeci
11:25 am - 11:50 am Cancer vaccines & combination with “standard of care” therapies. Sebastian Kreiter, BioNTech AG, Mainz, Germany
11:50 am - 12:15 pm Title not available. Özlem Türeci, BioNTech AG, Mainz, Germany
I wonder why 'Title not available' in the case of Ugur Sahin and Ozlem Tureci. Other familiar names - Cornelis J M Melief, Leiden Uni and Jennifer Wargo, M D Anderson.
http://www.cancerimmunotherapyconference.org/#third-cricimteatiaacr-international-cancer-immunotherapy-conference
6... Atabani ,Brentville, Chua,Cook , Durrant and Paston
Morning Crumbs, 4............and yes Samantha Pastons one got me excited. Which one am I missing? Is it a Wu or Xi?
Wow, can see another - Katherine Cook... so that is at least 6 abstracts.. I do not think we have ever done an event like this before!... wonder what all the abstracts can be about... just shows how much science is going on.... excited to get to see the posters
Ooh there are more Abstracts... me and boom got it to 4 already... but your right Sam Paston now has one too... got to be on TCR that surely..... Team scancell science there in force!
Victoria Brentville 27/9
Lindy Durrant 26/9
Samantha Paston 26/9
http://www.cancerimmunotherapyconference.org/program-of-events...............IRA MELLMAN PRESENTING
Could well get an RNS this morning re CICON......................Good Morning